Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] ANG 3777 in Healthy Males
NCT04931524Phase 1Unknown
- Sponsor
- Angion Biomedica Corp.
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of terevalefim in delayed graft function (DGF) and acute kidney injury (AKI), sponsored by Angion Biomedica Corp. Primary endpoints: Mass balance recovery of total radioactivity (TR) in urine, Mass balance recovery of total radioactivity (TR) in faeces and 6 more. Status: unknown.
02
Drugs
terevalefim
03
Conditions
delayed graft function (DGF)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04931524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931524.